Australia markets open in 2 hours 54 minutes

Catalyst Biosciences, Inc. (CBIO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.4835+0.0035 (+0.73%)
At close: 04:00PM EDT
0.4880 +0.00 (+0.93%)
After hours: 04:50PM EDT

Catalyst Biosciences, Inc.

611 Gateway Boulevard
Suite 710
South San Francisco, CA 94080
United States
650 871 0761
https://www.catalystbiosciences.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees45

Key executives

NameTitlePayExercisedYear born
Dr. Nassim Usman Ph.D.Pres, CEO & Director613.11kN/A1960
Ms. Seline E. Miller CPASr. VP of Fin., Interim Chief Financial & Principal Accounting Officer859.16kN/A1969
Dr. Grant Blouse M.Sc., Ph.D.Chief Scientific Officer484.66kN/AN/A
Dr. Howard Levy M.B.B.Ch., M.M.M., Ph.D.Consultant434.21kN/A1954
Ms. Ana KaporSr. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Dr. Tom Knudsen D.V.M., Ph.D.Sr. VP of Corp. Devel.N/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.

Corporate governance

Catalyst Biosciences, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.